Literature DB >> 23549440

Patient adherence to allergy immunotherapy.

William R Reisacher1, Jiovani M Visaya.   

Abstract

PURPOSE OF REVIEW: This article reviews the literature on patient adherence to two different approaches to allergen-specific immunotherapy for allergic disease. Factors related to adherence in general, as well as the various methods used to measure adherence, will be discussed. RECENT
FINDINGS: Although a complex interaction of factors related to both the physician and the patient influence the adherence to a particular therapeutic regimen, effective communication between these two parties and the simplicity of the regimen are frequently noted to be of primary importance. Variability with respect to the definition of adherence, the method of measuring adherence, and the length of the measuring period has resulted in a wide range of adherence rates to allergy immunotherapy reported in the literature. Patients most often site inconvenience, side-effects, and poor efficacy as reasons for discontinuing allergy immunotherapy.
SUMMARY: Adherence to therapy not only improves individual patient outcomes, but also helps determine the best treatment modalities and reduces the burden of disease on society. As new methods of delivering immunotherapy are being developed, such as allergy immunotherapy tablets and oral mucosal immunotherapy, the factors associated with patient adherence should be carefully considered.

Entities:  

Mesh:

Year:  2013        PMID: 23549440     DOI: 10.1097/MOO.0b013e32835f8048

Source DB:  PubMed          Journal:  Curr Opin Otolaryngol Head Neck Surg        ISSN: 1068-9508            Impact factor:   2.064


  15 in total

Review 1.  [Adherence in specific immunotherapy].

Authors:  M-L Lemberg; M-J Joisten; R Mösges
Journal:  Hautarzt       Date:  2017-04       Impact factor: 0.751

2.  Compliance with allergen immunotherapy and factors affecting compliance among patients with respiratory allergies.

Authors:  Fardous Musa; Mona Al-Ahmad; Nermina Arifhodzic; Waleed Al-Herz
Journal:  Hum Vaccin Immunother       Date:  2016-11-07       Impact factor: 3.452

3.  Adherence to subcutaneous immunotherapy with aeroallergens in real-life practice during the COVID-19 pandemic.

Authors:  Osman Ozan Yeğit; Semra Demir; Derya Ünal; Müge Olgaç; Kadriye Terzioğlu; Deniz Eyice Karabacak; Can Tüzer; Vehbi Ayhan; Bahattin Çolakoğlu; Suna Büyüköztürk; Aslı Gelincik
Journal:  Allergy       Date:  2021-05-10       Impact factor: 14.710

Review 4.  Use of new technology to improve utilization and adherence to immunotherapy.

Authors:  Smita Joshi; Ves Dimov
Journal:  World Allergy Organ J       Date:  2014-11-21       Impact factor: 4.084

5.  The effect of a new communication template on anticipated willingness to initiate or resume allergen immunotherapy: an internet-based patient survey.

Authors:  Moises A Calderon; Linda Cox; Thomas B Casale; Ralph Mösges; Oliver Pfaar; Hans-Jørgen Malling; Joaquin Sastre; Musa Khaitov; Pascal Demoly
Journal:  Allergy Asthma Clin Immunol       Date:  2015-05-22       Impact factor: 3.406

Review 6.  Management of the polyallergic patient with allergy immunotherapy: a practice-based approach.

Authors:  Pascal Demoly; Giovanni Passalacqua; Oliver Pfaar; Joaquin Sastre; Ulrich Wahn
Journal:  Allergy Asthma Clin Immunol       Date:  2016-01-11       Impact factor: 3.406

7.  Adherence and systemic reaction rates to allergy immunotherapy among veterans.

Authors:  Joseph T Ellenburg; Jay A Lieberman; Debendra Pattanaik
Journal:  Allergy Rhinol (Providence)       Date:  2016-01-01

8.  Real-life adherence to subcutaneous immunotherapy: What has changed in the era of the COVID-19 pandemic.

Authors:  Ilkay Koca Kalkan; Hale Ates; Kurtulus Aksu; Selma Yesilkaya; Musa Topel; Dilek Cuhadar Ercelebi; Suleyman Turkyilmaz; Ali Oncul; Senay Demir
Journal:  World Allergy Organ J       Date:  2021-06-08       Impact factor: 4.084

Review 9.  Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience.

Authors:  M Caminati; G Senna; G Stefanizzi; R Bellamoli; S Longhi; F Chieco-Bianchi; G Guarnieri; S Tognella; M Olivieri; C Micheletto; G Festi; E Bertocco; M Mazza; A Rossi; A Vianello
Journal:  BMC Pulm Med       Date:  2016-08-25       Impact factor: 3.317

10.  An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial.

Authors:  A M Chaker; B Al-Kadah; U Luther; U Neumann; M Wagenmann
Journal:  Clin Transl Allergy       Date:  2016-02-02       Impact factor: 5.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.